Enhancing Oncology Care for Prostate Cancer in Saudi Arabia

MENA

$0

gratuit

Non accrédité

45 min

Oncologie

0 Crédits

Description du cours

This presentation by esteemed experts, Dr. Fouad Alnajjar and Dr. Shouki Bazarbashi, delves into the urgent matter of prostate cancer in Saudi Arabia. The alarming statistics reveal a remarkable 30% rise in incidence over the past decade, warranting immediate attention. The speakers shed light on the significance of shared decision-making in screening, specifically emphasizing the target age group of 55 and above, who should undergo annual PSA blood tests. 

A comprehensive overview of treatment options for localized prostate cancer is presented, encompassing active surveillance, surgery, and radiation therapy, while advanced metastatic cases predominantly rely on potent hormonal therapies. The crucial role of pharmacists in patient care is acknowledged, with a focus on managing side effects, monitoring bone health, and offering essential lifestyle guidance. With a resolute emphasis on early detection and holistic patient care, this compelling presentation serves as a rallying call in the fight against prostate cancer in Saudi Arabia.


This program is supported by Novartis.

Détails du cours

Date d'expiration : 2024-07-26

Métiers: Pharmacie

Faculté

Dr. Fouad Alnajjar
Dr. Shouki Bazarbashi

Accréditation

<!--

This program is accredited by the Saudi Commission for Health Specialties for 2.0 CPD Hour(s). 
Activity Accreditation Number: ACA-20230002488. 

Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.


-->

Objectif(s) d'apprentissage

Upon completion of this continuing education program, participants will be better able to:

  • Review incidence of Prostate Cancer (PC). 
  • Discuss risk factors for PC. 
  • Décrire Saudi guidelines for PC treatment. 
  • Integrate practice considerations for pharmacists to address rising rates of PC.